Houston universities earn top marks for research and student opportunity

top of class

Five Houston universities were named among the Carnegie Foundation's top tier of research institutions. Photo courtesy UH.

The American Council on Education and the Carnegie Foundation for the Advancement of Teaching recently released its new Research Activity Designations, which named several Houston universities to its Very High Research Spending and Doctorate Production, or R1, tier.

The R1 status means that universities meet $50 million in total annual research spending and 70 research doctorates awarded annually. This year, 187 institutions were given the designation, according to the Carnegie Foundation.

The 2025 categorizations were made using an updated methodology to be "more reflective of the wide range of higher education institutions across America and how well they serve their students," according to a release. Until now, research activity was included in the foundations' Basic Classifications. This year was the first year the Research Activity Designations were published separately.

“These updates to the Carnegie Classifications are the first step to bring a decades-old system into the 21st century. We are expanding our recognition of the range of ways colleges and universities engage in research and development,” Timothy F.C. Knowles, president of the Carnegie Foundation, said in the release. “And we are taking the guesswork out of what it takes to be recognized as an R1 institution. Over time, this will be good for the sector, for scholarship, for policymakers and for students.”

Here are the Houston institutions to receive the R1 designation:

  • Baylor College of Medicine
  • Rice University
  • The University of Texas Health Science Center at Houston
  • The University of Texas MD Anderson Cancer Center
  • University of Houston

The foundation also released new Student Access and Earnings Classifications, which honor colleges that serve a student body representative of their local community and help achieve competitive post-graduation earnings.

UH was the only Houston college to earn the Opportunity College & University – Higher Access, Higher Earnings (OCU) designation, and was one of only 21 universities in the country to earn it in addition to the R1 status for research.

“Maintaining our new Opportunity College and University designation reflects our unwavering commitment to access and economic mobility for all students, while our R1 research status speaks to the strength of our faculty and the transformative scholarship happening on our campus,” UH president Renu Khator said in a news release.

Just 16 percent of U.S. colleges and universities received the OCU designation. The classification comes from publicly available data from the U.S. Department of Education’s College Scorecard, the Integrated Postsecondary Education Data System and the U.S. Census Bureau. The classification considers the percentage of Pell Grant recipients, the number of underrepresented students enrolled, the median undergraduate earnings eight years after enrollment and other factors.

“These recognitions help tell the full story of our institution’s impact,” Diane Z. Chase, senior vice president for academic affairs and provost at UH, added in the release. “UH is a powerhouse for ideas, innovation and opportunity. We are changing lives through discovery, access and economic mobility—not only for our students, but for the communities we serve.”

Comparatively, Rice earned a Lower Access, Higher Earnings designation. The other Houston universities were not classified in the Student Access and Earnings Classifications.

In 2024, Rice University was one of 25 U.S. colleges and universities to receive the first Carnegie Leadership for Public Purpose Classification. The classification highlights colleges that have committed to “campus-wide efforts to advance leadership in pursuit of public goods like justice, equity, diversity and liberty.” Read more here.

From Your Site Articles
The new collaborative hub will foster research into cell therapies, artificial intelligence, nanotechnologies, and more. Photo via tmc.edu

Houston health care leaders announce new hub for cancer-fighting bioengineering

team work

Two Houston organizations recently announced a new hub that will focus on developing cell therapies, nanotechnologies, cancer vaccines, artificial intelligence, and molecular imaging.

Rice University and The University of Texas MD Anderson Cancer Center have teamed up to “drive industry growth and advance life-saving technologies” through the newly established Cancer Bioengineering Collaborative, according to a news release announcing the initiative.

The collaboration between the two institutions includes fundamental and translational cancer research, developing new technologies for cancer detection and therapy, and securing external funding in support of further research and training.

Leading the hub will be Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem.

“There is tremendous potential in bringing together experts in engineering and cancer as part of this focused, collaborative framework that is truly unique, not only owing to the complementary nature of the respective strengths but also because this is the first formal joint research initiative of its kind between the two institutions,” says Bao, department chair and Foyt Family Professor of Bioengineering, professor of chemistry, materials science and nanoengineering and mechanical engineering, in the release.

The joint effort will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering, and also a seed grant program to fund research projects in the early stages of development.

“From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, says in the release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.”

Dr. Jeff Molldrem (left) and Gang Bao will lead the new collaborative hub. Photo via MD Anderson

The design and construction team has been announced for TMC3. Courtesy of Elkus Manfredi Architects

Texas Medical Center reveals new details and renderings for its TMC3 campus

Coming to hou in 2022

The Texas Medical Center just announced the dream team of architects and designers that are making TMC3 into a reality.

Elkus Manfredi Architects, Transwestern, and Vaughn Construction are the three companies that will serve as the architectural and development team for the 37-acre research campus. TMC3's founding institutions — TMC, Baylor College of Medicine, Texas A&M University Health Science Center, The University of Texas Health Science Center at Houston, and The University of Texas MD Anderson Cancer Center — decided on the three entities.

"Texas Medical Center is eager to move forward with a bold, imaginative and dynamic new design vision for the TMC3 Master Plan," says TMC CEO and president, Bill McKeon, in a press release. "With the combined talents of Elkus Manfredi Architects, Transwestern, and Vaughn Construction on-board, I couldn't be more confident that this dream team will flawlessly execute the totality of the project's vision and fulfill its mission to bring together leading researchers and top-tiered expertise from the private sector to create the number one biotechnology and bioscience innovation center in the entire world."

TMC3 was first announced just over a year ago and is planned to open in 2022. The campus will incorporate research facilities, retail space, residential plans, a hotel and conference center, and green space. Parking will be underground to optimize surface area.

Design in mind

The 37-acre research campus will be interconnected by a DNA helix outdoor promenade.

Courtesy of Elkus Manfredi Architects

From a design perspective, the key element will be a DNA helix-shape that looks like a necklace chain that connects the campus.

"Our idea was to expand on the DNA design concept and create a series of spaces that would elongate the strand all the way north to the historic core of the Texas Medical Center and south to the new development by UTHealth and MD Anderson in order to create more opportunity for connections and collisions," says Elkus Manfredi Architects CEO and founding principal, David Manfredi, in the release. "We're implementing the connective tissue between all these places and establishing opportunities for unplanned interactions. Science, technology, medicine, discovery and innovation are all about making connections, and we are building a space for institutions, industry and startups to interact."

Manfredi's firm is responsible for a few other iconic medical facilities, such as the original Broad Institute of MIT and Harvard and The Stanley Building at the Broad Institute in Cambridge, Massachusetts, and the New York Genome Center.

"We want to create spaces that attract talent," Manfredi says in the release. "You can attract talent with great colleagues, research and facilities, but if you don't have a great social environment for people to live, learn, and play, people move on. We are creating a place where people will want to be because they're constantly stimulated – whether it's breakfast at the local coffee shop, or a volleyball league in the afternoon, or working in a central lab and the person next to them is doing something intersects with their own research."

Growing partner institutions

TMC3 Collaborative will be a centrally located building on the campus that is designed to host gatherings and share space with industry leaders.

Courtesy of Elkus Manfredi Architects

While a big portion of the attraction in the new campus is this multi-purposeful and connective space, the project opens doors for the five partner institutions. For Baylor College of Medicine, TMC3 means an expansion of its facilities and an increased footprint for Baylor St. Luke's Medical Center's McNair Campus. The second tower of the hospital will be right at TMC3's eastern edge.

"The selection of a development team is an important milestone for the TMC3 project," says Paul Klotman, president, CEO and executive dean of Baylor College of Medicine, in the release. "The project itself is a huge step in developing the biotech industry in Houston. At Baylor, we look forward to working closely with TMC leaders, as well as those of the other anchor institutions, in making this project a reality."

Additionally, the Texas A&M Health Science Center research building — led by Carrie L. Byington, M.D — on the north end adjacent to BCM's building and the hotel and conference center. On the south side of the campus, MD Anderson and UTHealth will each develop new research facilities that will connect to the existing University of Texas Research Park that is directly to the south of the campus. UT Research Park will be connected to TMC3 via a new skybridge.

The release also describes a central building dubbed TMC3 Collaborative that will create collaborative research space for industry partners. The first level of the building will be an open atrium for gatherings and have food and beverage concepts.

"When TMC3 opens in 2022, Texas Medical Center will officially plant a tangible flag that signals its arrival as the Third Coast for life sciences for the foreseeable future," McKeon says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.
View All Listings